Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 1506-1507, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, Y. P.
Right arrow Articles by Ullman, E. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, Y. P.
Right arrow Articles by Ullman, E. F.
(Clinical Chemistry. 2000;46:1506-1507.)
© 2000 American Association for Clinical Chemistry, Inc.

Abstracts of Oak Ridge Posters

Homogeneous, Rapid Luminescent Oxygen Channeling Immunoassay (LOCITM) for Homocysteine

Yen Ping Liua, Steve de Keczer1, Svetlana Alexander1, Marcel Pirio1, Dariush Davalian1, Nurith Kurn1 and Edwin F. Ullman1

1 Advanced Diagnostics Division, Dade Behring Inc., PO Box 49013, San Jose, CA 95161
a author for correspondence: fax 408-239-2707, e-mail yenping_liu@dadebehring.com

Homocysteine (Hcy) is present in plasma primarily bound as disulfides with itself, Cys, and albumin (~70%) (1)(2)(3)(4). Total homocysteine (tHcy) in serum or plasma is markedly increased in patients with cobalamin or folate deficiency (3), and decreases only when they are treated with the deficient vitamin. tHcy is therefore of clinical relevance, with reference values in fasting subjects of ~5–15 µmol/L (1). In addition, even a moderate increase of Hcy (hyperhomocysteinemia) is a risk factor for premature cardiovascular disease (4). These disorders justify introduction of the tHcy assay in the routine clinical chemistry laboratory.

The development of a rapid, homogeneous assay for Hcy in serum or plasma using the luminescent oxygen channeling immunoassay (LOCITM) (5) is described. An ELISA for the determination of tHcy based on the modification of sample tHcy by alkylation and detection of the alkylated product was described previously (6).

The current assay is designed for tHcy determination in serum or plasma at clinically relevant concentrations. Chemical reactions involved in the assay can be divided into three steps:

The first step involves the release of bound Hcy by reduction of serum disulfides with tris-(2-carboxyethyl)phosphine (TCEP); the second step involves the . . . [Full Text of this Article]


Acknowledgments


References




The following articles in journals at HighWire Press have cited this article:


Home page
 J Biomol ScreenHome page
J. F. Glickman, X. Wu, R. Mercuri, C. Illy, B. R. Bowen, Y. He, and M. Sills
A Comparison of ALPHAScreen, TR-FRET, and TRF as Assay Methods for FXR Nuclear Receptors
J Biomol Screen, February 1, 2002; 7(1): 3 - 10.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
N. Matsuyama, M. Yamaguchi, M. Toyosato, M. Takayama, and K. Mizuno
New Enzymatic Colorimetric Assay for Total Homocysteine
Clin. Chem., December 1, 2001; 47(12): 2155 - 2156.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.